World Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 15(7), P. 786 - 789
Published: July 16, 2024
The review article by Pavlidis
Language: Английский
World Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 15(7), P. 786 - 789
Published: July 16, 2024
The review article by Pavlidis
Language: Английский
World Journal of Experimental Medicine, Journal Year: 2024, Volume and Issue: 14(3)
Published: Aug. 28, 2024
Anaplastic thyroid cancer (ATC) is an aggressive, rare malignancy associated with rapid growth and metastasis, a very poor prognosis. We investigated the clinical characteristics, survival outcomes independent prognostic factors anaplastic cancer.
Language: Английский
Citations
0Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2820 - 2820
Published: Dec. 12, 2024
Pazopanib, a multi-targeted tyrosine kinase inhibitor, has been explored for its efficacy in treating various subtypes of thyroid cancer, including differentiated carcinoma (DTC), medullary (MTC), and anaplastic (ATC). This systematic review assesses the safety pazopanib, focusing on progression-free survival (PFS), overall (OS), response rates adverse events. A comprehensive search was conducted databases PubMed, Scopus, Web Science up to October 2024 identify randomized controlled trials phase II clinical that investigated use pazopanib cancer. The PRISMA guidelines were followed data extraction quality assessment. included six studies encompassing 289 patients, presenting overview pazopanib’s application across different cancer subtypes. reported median PFS ranging from 2.1 11.7 months OS 5.7 not reached. partial varied 5% 49%. Adverse events common, with hypertension occurring 71.7% fatigue diarrhea also frequently reported. Grade 3–5 led treatment discontinuations 14% patients. Pazopanib shows variable types, offering significant benefits MTC refractory DTC terms but limited impact ATC. event profile necessitates careful management, particularly regarding other treatment-related toxicities. Further are required refine therapeutic protocols exploring combination therapies may enhance reduce outcomes.
Language: Английский
Citations
0World Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 15(7), P. 786 - 789
Published: July 16, 2024
The review article by Pavlidis
Language: Английский
Citations
0